Clinical Trial: To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: To Compare the Efficacy and Safety of TW vs Valsartan in the MN

Brief Summary: The purpose of this study is to assess the efficacy of TW compared to Valsartan in treatment of heavy proteinuria of membranous nephropathy.

Detailed Summary:

Membranous nephropathy with heavy proteinuria have high risks of progressing to CRF.

Tripterygium (TW) is a Chinese traditional patent drugs, it can reduce proteinuria of chronic glomerular nephritis,such as IgA nephropathy. So, we designed this randomized, prospective clinical trial to assess the efficacy and safety of TW versus Valsartan in the treatment of heavy proteinuria of MN.

Sponsor: Nanjing University School of Medicine

Current Primary Outcome: To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of membranous nephropathy [ Time Frame: 12 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: To investigate the safety and tolerability of TW vs ARB in treatment of MN [ Time Frame: 12 months ]

Original Secondary Outcome: Same as current

Information By: Nanjing University School of Medicine

Dates:
Date Received: August 16, 2007
Date Started: July 2007
Date Completion:
Last Updated: May 25, 2010
Last Verified: March 2009